Tech Company Financing Transactions
Mana.bio Funding Round
On 10/12/2023, Mana.bio raised $19.5 million in Seed investment from Andreessen Horowitz, LionBird and NFX.
Transaction Overview
Company Name
Announced On
10/12/2023
Transaction Type
Venture Equity
Amount
$19,500,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to advance development of its proprietary, purpose-built AI LNP platform to deliver RNA and gene therapies to specific extrahepatic tissues in the body.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Tel Aviv, Undisclosed
IL
Tel Aviv, Undisclosed
IL
Phone
Undisclosed
Website
Email Address
Overview
Mana.bio is an AI based drug delivery startup, focusing on gene therapy including DNA and RNA-based therapeutics, and vaccines. Mana.bio is a seed stage biotech company leveraging data, machine learning and high throughput screening to design novel LNPs for targeted extrahepatic delivery of nucleic acid therapeutics and vaccines.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Yogev Debbi
Chief Technical Officer
Roy Nevo
Browse more venture capital transactions:
Prev: 10/12/2023: Natrx venture capital transaction
Next: 10/12/2023: Luna POS venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs